Delivery Order SPE2DB22D1017-SPE2DB25FYPHM
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,542.97 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. As a child delivery order under a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90 units, with a ceiling value of $2,484.03. This is a firm fixed price delivery order with no set-aside designation, issued as a competitive award. The place of performance is AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets in a quantity of 90 tablets, with a contract ceiling value of $1,393.20. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- This delivery order, awarded July 21, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides 90 tablets of Valsartan-HCTZ 160-12.5 mg with a ceiling value of $8,953.53. The contract is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is a child contract under AmerisourceBergen...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Valsartan-HCTZ 80-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, valued at $3,321.82, represents a non-competitive set-aside contract and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90 units, with a ceiling value of $1,697.07. This competitively awarded, firm fixed-price contract is classified as non-set-aside and was completed on August 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the delivery order from its location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) valued at $5,573.64. This is a firm fixed-price delivery order with no set-aside designation, and the product is scheduled for delivery by July 29, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets in a 90-count quantity, with a ceiling value of $8,641.99. This firm fixed-price delivery order, which is not set-aside designated, represents a continuation of AmerisourceBergen's pharmaceutical supply support under its larger contract vehicle with the DLA. Performance will be executed from the contractor's Conshohocken, Pennsylvania...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency Medical Supply Chain on July 21, 2025, for Valsartan-HCT 320-25 mg tablets in a 90-count supply. The contract is valued at $3,709.25 and operates under a firm fixed-price delivery order structure with an ultimate completion date of July 22, 2025. This award represents a non-set-aside, competitively awarded contract, demonstrating the vendor's continued capability...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets in a quantity of 90 units, with a contract value of $8,635.00. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025....
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPHMDelivery Order
This delivery order, awarded August 27, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides 90-count tablets of Valsartan-HCTZ 160-25 mg with a ceiling value of $3,617.52. The award is a firm fixed price, non-competitive set-aside delivery order executed under AmerisourceBergen's $999.99 billion indefinite delivery contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026. This parent contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency, military healthcare systems, and other government entities. The delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania facility with an ultimate completion date of August 28, 2025. Valsartan-HCTZ is a combination antihypertensive medication used to treat high blood pressure, reflecting DLA's ongoing procurement of essential pharmaceuticals to support military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 8/27/25 |